Sunshine Biopharma, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a revenue increase of 11.6% to $9.4 million for the quarter, compared to $8.4 million in the same period last year. For the nine-month period, revenue rose by 9.7% to $27.7 million from $25.3 million. The company attributed this growth to enhanced marketing efforts and improved procurement strategies that reduced the cost of goods sold, which decreased from 70% to 66.7% of total revenue for the nine-month period.
Despite the revenue growth, Sunshine Biopharma reported a net loss of $883,820 for the third quarter, a 24% improvement from the loss of $1.2 million in the same quarter of 2024. For the nine-month period, the net loss was $3.8 million, compared to a loss of $3 million in the prior year. The increase in losses was primarily driven by a significant impairment of intangible assets amounting to $1.6 million, reflecting the company's assessment that certain product licenses could not be commercialized. General and administrative expenses also rose, totaling $13.7 million for the nine months, up from $11.4 million in 2024.
Operationally, Sunshine Biopharma continues to expand its product offerings, with 76 generic prescription drugs currently on the market in Canada through its subsidiary, Nora Pharma. The company is also developing proprietary drugs, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. The company plans to launch an additional 12 drugs in 2026, which it anticipates will strengthen its position in the Canadian generic drug market, valued at approximately $9.7 billion.
As of September 30, 2025, Sunshine Biopharma had cash and cash equivalents of $9.3 million, a decrease from $9.7 million at the end of 2024. The company reported net cash used in operating activities of $3.7 million for the nine months, a significant reduction from $9.1 million in the same period last year. Sunshine Biopharma's financing activities generated $4 million during the nine months, down from $7.3 million in 2024, primarily due to a smaller financing event. The company indicated that it expects its existing cash and revenue generation to be sufficient to fund operations for the next 24 months, although it may need to raise additional capital for future research and development and expansion efforts.
About Sunshine Biopharma, Inc
Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing generic, OTC, and proprietary medicines across therapeutic areas such as oncology and antivirals. It owns a portfolio of approved generics in Canada, develops novel drug candidates including mRNA-based cancer therapies and coronavirus inhibitors, and seeks to expand its market presence through licensing, licensing agreements, and strategic partnerships. The company emphasizes innovation, regulatory compliance, and competitive positioning in global markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.